Serbian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
dimethyl sulfoxide/рак
Веза се чува у привремену меморију
Страна 1 од 18 резултати
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
PRIMARY OBJECTIVE:
I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.
SECONDARY OBJECTIVES:
I. To evaluate the proportion of patients alive and progression free at 6 months of
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
PRIMARY OBJECTIVE:
I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.
SECONDARY OBJECTIVES:
I. To evaluate the proportion of patients alive and progression free at 6 months of
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
PRIMARY OBJECTIVE:
I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.
SECONDARY OBJECTIVES:
I. To evaluate the proportion of patients alive and progression free at 6 months of
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
PRIMARY OBJECTIVE:
I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.
SECONDARY OBJECTIVES:
I. To evaluate the proportion of patients alive and progression free at 6 months of
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
PRIMARY OBJECTIVE:
I. To estimate the event-free survival (EFS) distribution for newly-diagnosed patients with BRAFV600-mutant high-grade glioma (HGG) without H3 K27M mutations excluding anaplastic pleomorphic xanthoastrocytoma (aPXA) and anaplastic ganglioglioma (aGG) treated with radiation therapy
Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
PRIMARY OBJECTIVES:
I. To study the efficacy and safety of dabrafenib mesylate (dabrafenib) and trametinib dimethyl sulfoxide (trametinib) as combination therapy in patients with BRAF V600E positive Erdheim Chester disease.
II. To determine the clinical response rate to dabrafenib and trametinib
Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Aim 1: Evaluation of cell-intrinsic mechanisms on BM.
1. Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) will be performed on marker CD138+ purified cells to evaluate their genomic profile, and on buccal swab DNA to restrict the analysis to variants or structural abnormalities that
Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
The study will be a randomized, placebo-controlled, double-blinded clinical pivotal trial. Patients will be allocated in a ratio of 1:1 to the melatonin or placebo group. Patients will be stratified according to the type of surgery (lumpectomy or mastectomy). Randomization will be performed in
Fertility Preservation in Prepubertal Boys: An Experimental Approach
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
As treatment regimens for pediatric oncologic malignancies have improved, more and more survivors are entering their reproductive years. Since gonadal damage is a relatively common and unfortunate consequence of the treatments used to cure pediatric cancer as well as certain hematological conditions
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
PRIMARY OBJECTIVE:
I. To determine whether initial treatment with either combination ipilimumab + nivolumab (with subsequent dabrafenib mesylate [dabrafenib] in combination with trametinib dimethyl sulfoxide [trametinib]) or dabrafenib in combination with trametinib (with subsequent ipilimumab +
Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Bacillus Calmette-Guérin (BCG) is considered the most effective treatment to increase disease-free interval and reduce progression of non-muscle invasive bladder cancer (NMIBC) [1]. Although considered safe, BCG can produce both local and systemic side effects leading to treatment discontinuation or
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
This study proposes a nontoxic immunotherapeutic approach to extend overall survival in patients in complete remission. Most patients with ovarian cancer achieve complete clinical remission after optimal debulking surgery and first-line platinum-based chemotherapy. However, most patients, despite
Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatment
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Actinic keratosis is a skin lesion induced by chronic sun exposure with a significant prevalence and malignant potential for squamous cell carcinoma, which makes essential its treatment. Today there are several possible therapies, where cryotherapy is usually applied in our practice. Photodynamic
Cell Samples From Patients With Leukemia
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
OBJECTIVES:
- Demonstrate the capability of primary human leukemia samples to survive and proliferate in the zebrafish embryo.
- Confirm the anti-proliferative or toxic effects of known chemotherapeutics on the transplanted cells in vivo.
- Evaluate the effect of novel anticancer drugs and/or their
Најкомплетнија база лековитог биља подржана науком
- Ради на 55 језика
- Биљни лекови потпомогнути науком
- Препознавање биљака по слици
- Интерактивна ГПС мапа - означите биље на локацији (ускоро)
- Читајте научне публикације повезане са вашом претрагом
- Претражите лековито биље по њиховим ефектима
- Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима
Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима
